Breaking News

TQ Therapeutics Acquires Juno Therapeutics

Acquisition supports TQ Therapeutics’ development of an ultra-short extracorporeal cell and gene therapy platform.

Author Image

By: Charlie Sternberg

Associate Editor

TQ Therapeutics GmbH (TQx), a biotechnology company dedicated to advancing the field of cellular therapies through innovative technologies, has acquired Juno Therapeutics GmbH, a cell therapy company, through a share purchase agreement. Juno GmbH is a German subsidiary of Juno Therapeutics, Inc., which is a wholly owned subsidiary of the global biopharmaceutical company, Bristol Myers Squibb. The financial terms of the agreement were not disclosed. The acquisition of Juno GmbH will increas...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters